No Data
10-Q: Q2 2024 Earnings Report
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients With Inflammatory Bowel Disease
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (Fremanezumab) SPACE Trial for Prevention of Episodic Migraine
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 A.m. ET on July 31, 2024
New AJOVY (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
No Data
No Data